Perspective Therapeutics (CATX) Enterprise Value (2010 - 2026)

Perspective Therapeutics has disclosed Enterprise Value across 17 years of filings, most recently posting -$36.3 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 63.33% year-over-year to -$36.3 million; the TTM figure through Jun 2026 stood at -$36.3 million (up 63.33% YoY), while the FY2025 annual figure was $59.7 million, up 4149.62% from the prior year.
• Enterprise Value came in at -$36.3 million for Q2 2026 at Perspective Therapeutics, down from -$12.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $592.8 million in Q3 2024 to a low of -$221.3 million in Q1 2025.
• Average Enterprise Value over 5 years is $83.0 million, with a median of -$4.6 million recorded in 2022.
• Year-over-year, Enterprise Value sank 177.3% in 2022 and soared 4149.62% in 2025.
• Over 5 years, Enterprise Value stood at -$8.2 million in 2022, then surged by 1357.61% to $103.5 million in 2023, then plunged by 101.42% to -$1.5 million in 2024, then soared by 4149.62% to $59.7 million in 2025, then tumbled by 160.74% to -$36.3 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$36.3 million in Q2 2026, -$12.4 million in Q1 2026, and $59.7 million in Q4 2025.